<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505099</url>
  </required_header>
  <id_info>
    <org_study_id>AVXS-101-CL-304</org_study_id>
    <nct_id>NCT03505099</nct_id>
  </id_info>
  <brief_title>Pre-Symptomatic Study of Intravenous AVXS-101 in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2</brief_title>
  <acronym>SPR1NT</acronym>
  <official_title>A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AveXis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AveXis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A global study of intravenous AVXS-101 in pre-symptomatic patients with SMA with 2, 3, and 4
      copies of SMN2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, open-label, single-arm study of a single, one-time dose of AVXS-101 (gene
      replacement therapy) in patients with spinal muscular atrophy (SMA) who meet enrollment
      criteria and are genetically defined by bi-allelic deletion of SMN1 with 2, 3, or 4 copies of
      survival motor neuron 2 gene (SMN2). Patients with SMN1 point mutations or the SMN2 gene
      modifier mutation (c.859G&gt;C) may enroll but will not be included in the efficacy analysis
      sets.

      The study will enroll at least fifteen (15) patients with 2 copies of SMN2 that meet the
      Intent To Treat (ITT) criteria, at least twelve (12) patients with 3 copies of SMN2 that meet
      the ITT criteria and at least seventeen (17) patients with 4 copies of SMN2 that meet the ITT
      criteria. Patients in all three cohorts must be ≤6 weeks of age at the time of gene
      replacement therapy (Day 1).

      The study includes a screening period, a gene replacement therapy period, and a follow-up
      period. During the screening period (Days -30 to -2), patients whose parent(s)/legal
      guardian(s) provide informed consent will undergo screening procedures to determine
      eligibility for study enrollment. Patients who meet the entry criteria will enter the
      in-patient gene replacement therapy period (Day -1 to Day 2). On Day -1, patients will be
      admitted to the hospital for pre-treatment baseline procedures. On Day 1, patients will
      receive a single, one-time intravenous (IV) infusion of AVXS-101, and will undergo in-patient
      safety monitoring for a minimum of 24 hours post infusion. Patients may be discharged 24
      hours after the infusion, based on Investigator judgment. During the outpatient follow-up
      period (Days 3 to End of Study at 18, 24 or 36 months of age, dependent upon respective SMN2
      copy number), patients will return at regularly scheduled intervals for efficacy and safety
      assessments until the End of Study when the patient reaches 18 months of age (SMN2 = 2), 24
      months of age (SMN2 = 3) or 36 months of age (SMN2 = 4). After the End of Study visit,
      eligible patients will be asked to rollover into a long-term follow up study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 copies SMN2 gene: functional independent sitting</measure>
    <time_frame>18 months of age</time_frame>
    <description>Proportion of patients demonstrating functional independent sitting for at least 30 seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3 copies of SMN2 gene: standing without support</measure>
    <time_frame>24 months of age</time_frame>
    <description>Proportion of patients achieving the ability to stand without support for at least three seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4 copies of SMN2 gene: demonstrating motor improvements inconsistent with SMA natural history</measure>
    <time_frame>36 months of age</time_frame>
    <description>Proportion of patients demonstrating the ability to achieve a scaled score on Bayley V.3 Gross and Fine Motor Subtests within 1.5 standard deviations of chronological development reference standard</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>AVXS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time intravenous infusion of AVXS-101 at 1.1 X 1014 vg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVXS-101</intervention_name>
    <description>A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.</description>
    <arm_group_label>AVXS-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤6 weeks (≤42 days) at time of dose

          -  Ability to tolerate thin liquids as demonstrated through a formal bedside swallowing
             test

          -  Compound muscle action potential (CMAP) ≥2mV at Baseline; centralized review of CMAP
             data will be conducted

          -  Gestational age of 35 to 42 weeks Patients with 2 copies of SMN2 (n ≥15)

               -  Patients with pre-symptomatic SMA Type 1 as determined by the following features:

                  − 2 copies of SMN2 Patients with 3 copies of SMN2 (n ≥12)

               -  Patients with pre-symptomatic SMA Type 2 as determined by the following features:

                  − 3 copies of SMN2 Patients with 4 copies of SMN2 (n ≥17)

               -  Patients with pre-symptomatic SMA Type 3 as determined by the following features:

                    -  4 copies of SMN2

        Exclusion Criteria:

          -  Weight at screening visit &lt;2 kg

          -  Hypoxemia (oxygen saturation &lt;96% awake or asleep without any supplemental oxygen or
             respiratory support) at the screening visit or for altitudes &gt;1000 m, oxygen
             saturation &lt;92% awake or asleep without any supplemental oxygen or respiratory support
             at the screening visit

          -  Any clinical signs or symptoms at screening or immediately prior to dosing that are,
             in the opinion of the Investigator, strongly suggestive of SMA (e.g., tongue
             fasciculation, hypotonia, areflexia)

          -  Tracheostomy or current prophylactic use or requirement of noninvasive ventilatory
             support at any time and for any duration prior to screening or during the screening
             period

          -  Patients with signs of aspiration/inability to tolerate nonthickened liquids based on
             a formal swallowing test performed as part of screening or patients receiving any
             non-oral feeding method

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters as
             determined by investigator or medical monitor

          -  Treatment with an investigational or commercial product, including nusinersen, given
             for the treatment of SMA. This includes any history of gene therapy, prior antisense
             oligonucleotide treatment, or cell transplantation.

          -  Patients whose weight-for-age is below the third percentile based on World Health
             Organization (WHO) Child Growth Standards [25]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Feltner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AveXis, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AveXis MedInfo</last_name>
    <phone>833-828-3947</phone>
    <email>medinfo@avexis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shirley Paulose</last_name>
      <phone>650-724-3792</phone>
      <email>spaulose@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn McLaughlin Savage</last_name>
      <email>cjmclaug@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Berry</last_name>
      <phone>407-650-7523</phone>
      <email>Debbie.Berry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Rare Neurological Diseases</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Hardy</last_name>
      <phone>770-713-3653</phone>
      <email>lisa@rareneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington Unviersity School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pallavi Anand</last_name>
      <phone>314-362-2490</phone>
      <email>anandp@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Krupka</last_name>
      <phone>212-305-6421</phone>
      <email>djk2137@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Berry</last_name>
      <phone>212-342-3038</phone>
      <email>kb2996@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Chiriboga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christie Milleson</last_name>
      <phone>919-684-2687</phone>
      <email>christie.milleson@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Loren Pena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beverly Galliers</last_name>
      <phone>614-355-3424</phone>
      <email>beverly.galliers@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jerry R Mendell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Ramm</last_name>
      <phone>214-456-4426</phone>
      <email>Tammy.Ramm@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bryant Gordon</last_name>
      <phone>801-585-5052</phone>
      <email>Bryant.Gordon@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin (Madison)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connstance Trantow</last_name>
      <phone>608-265-7814</phone>
      <email>cbt@clinicaltrials.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Meredith Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospitals Network and</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Farrar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropédiatrie - Centre de Référence des Maladies Neuromusculaires</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Catherine Defeldre</last_name>
      <email>Anne.Catherine.Defeldre@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sharon Aharoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kayoko Saito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Children's Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnamdo</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jin-Hong Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Area Genetica Clínica y Molecular</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scherezade Sarri</last_name>
      <email>scherezade.sarri@vhir.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yin-Hsiu Chien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

